Affinage

JDP2

Jun dimerization protein 2 · UniProt Q8WYK2

Length
163 aa
Mass
18.7 kDa
Annotated
2026-06-10
63 papers in source corpus 33 papers cited in narrative 33 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JDP2 is a bZIP transcription factor that binds AP-1/ATF-CRE cis-elements and acts predominantly as a transcriptional repressor through chromatin-level mechanisms, thereby controlling differentiation, proliferation, stress responses, and redox homeostasis across multiple lineages (PMID:12052888, PMID:23200825, PMID:20802531). It represses target promoters by recruiting an HDAC3 complex and by directly inhibiting p300-mediated acetylation of core histones through its N-terminal region and DNA-binding domain, activities complemented by intrinsic histone-chaperone (nucleosome-assembly) activity (PMID:12052888, PMID:16518400). Through these mechanisms JDP2 suppresses c-jun, ATF3, cyclin-A2, C/EBPδ, and CHOP transcription, and silences higher-order chromatin states such as Polycomb-mediated repression of the p16Ink4a/p19Arf locus, with corresponding control of retinoic-acid differentiation, osteoclastogenesis and neutrophil differentiation, adipogenesis, cell-cycle progression, and replicative senescence (PMID:12052888, PMID:23200825, PMID:19233846, PMID:20802531, PMID:17464331, PMID:18396163). JDP2 activity is gated by JNK, which phosphorylates Thr148 to target the protein for proteasomal degradation, and by the RING-finger ubiquitin ligase IRF2BP1 (PMID:11602244, PMID:21463260, PMID:18671972). Its DNA-binding specificity and transcriptional output are tuned by partner exchange: it heterodimerizes with c-JUN, ATF7, CHOP10, and ATF2, and interacts with the progesterone receptor, p53, and chromatin-modifying complexes (PMID:18463134, PMID:19553667, PMID:28007961, PMID:38473360, PMID:38801077). JDP2 also functions in genotoxic and oxidative stress: ATM-phosphorylated JDP2 nucleates a β-catenin/JDP2/PRMT5 complex that recruits WDR5/MLL to install activating histone methylation at glutathione-metabolic genes, restoring redox balance (PMID:31434880). In disease contexts it represses Trp53 and activates MCL1 to promote leukemic survival and steroid resistance (PMID:22370638, PMID:29941549).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2001 High

    Establishing how JDP2 is regulated post-translationally, JNK was shown to directly phosphorylate JDP2 at a defined residue, placing it downstream of stress kinase signaling.

    Evidence In vitro and in vivo kinase assays with T148A mutagenesis

    PMID:11602244

    Open questions at the time
    • Functional consequence of Thr148 phosphorylation not resolved here
    • Identity of the relevant JNK isoform not defined
  2. 2001 Medium

    JDP2 was placed in the survival pathway by showing it represses the p53 promoter through an atypical AP-1 site, defining an early transcriptional-repressor function.

    Evidence Reporter assay and UV-induced cell viability with overexpression

    PMID:11287607

    Open questions at the time
    • No direct DNA-binding/occupancy confirmation at the endogenous promoter
    • Physiological relevance beyond UV challenge unclear
  3. 2002 High

    The core repression mechanism was defined: JDP2 recruits HDAC3 to a target promoter and is displaced by p300 upon differentiation cues, linking JDP2 to dynamic histone acetylation control.

    Evidence ChIP, co-IP, and reporter assays in RA-treated F9 cells

    PMID:12052888

    Open questions at the time
    • Direct biochemical interaction surface with HDAC3 not mapped
    • Generality across other promoters not yet shown
  4. 2006 High

    JDP2 was shown to act intrinsically on chromatin — directly inhibiting p300 acetyltransferase activity and assembling nucleosomes — establishing it as a bona fide chromatin regulator, not merely a DNA-binding adaptor.

    Evidence In vitro/in vivo acetylation assays, nucleosome assembly assay, deletion mutagenesis

    PMID:16518400

    Open questions at the time
    • Structural basis of INHAT-like inhibition not solved
    • Relative in vivo contribution of HDAC recruitment vs direct p300 inhibition unquantified
  5. 2007 High

    Linking the chromatin mechanism to a developmental program, JDP2 was shown to restrain adipogenesis by deacetylating the C/EBPδ promoter.

    Evidence Jdp2 KO MEFs, ChIP for H3 acetylation, adipocyte differentiation and reporter assays

    PMID:17464331

    Open questions at the time
    • Upstream signals controlling JDP2 at this locus not defined
  6. 2008 High

    Partner-dependent functional switching was demonstrated: heterodimerization with CHOP10 converts JDP2 into a TRE-selective activator that opposes CHOP10-driven apoptosis under ER stress.

    Evidence Co-IP, EMSA, ChIP, reporter and viability assays

    PMID:18463134

    Open questions at the time
    • In vivo relevance of the JDP2-CHOP10 complex not tested
    • Determinants of TRE vs CRE selectivity incompletely defined
  7. 2008 Medium

    A degradation route was added by identifying IRF2BP1 as a RING-finger ubiquitin ligase for JDP2, defining a JNK-independent control of JDP2 levels.

    Evidence Tagged pulldown, polyubiquitination and reporter assays

    PMID:18671972

    Open questions at the time
    • Single pulldown without reciprocal validation
    • Endogenous regulation and physiological context unaddressed
  8. 2009 High

    JDP2 was connected to senescence control, showing its absence permits Polycomb (PRC1/PRC2) repression of p16Ink4a, defining an epigenetic gatekeeper role.

    Evidence Jdp2 KO MEFs, ChIP for H3K27me and PRC binding, overexpression

    PMID:19233846

    Open questions at the time
    • Mechanism by which JDP2 antagonizes PRC recruitment unresolved
  9. 2009 High

    Direct promoter occupancy at consensus and non-consensus sites was demonstrated for ATF3 repression, and structural mapping defined how JDP2 engages the progesterone receptor CTE to modulate its activity.

    Evidence KO/transgenic mice with reporter assays (ATF3); NMR chemical-shift mapping and CTE swaps (PR)

    PMID:19233874 PMID:19553667

    Open questions at the time
    • Whether PR enhancement uses the same chromatin machinery as repression unknown
  10. 2010 High

    A proliferation-control axis was established by showing JDP2 occupies and represses the cyclin-A2 promoter in vivo, restraining cell-cycle progression.

    Evidence Jdp2 KO mice, ChIP, qRT-PCR, rescue re-expression

    PMID:20802531

    Open questions at the time
    • Coordination with other cell-cycle targets not mapped
  11. 2011 High

    The fate of Thr148 phosphorylation was resolved: it targets JDP2 for proteasomal degradation, coupling stress-kinase signaling to JDP2 turnover.

    Evidence Phospho-mimetic/non-phosphorylatable mutants, kinase/proteasome inhibitors, CHX chase

    PMID:21463260

    Open questions at the time
    • The ubiquitin ligase acting on phospho-JDP2 not identified in this study
  12. 2011 High

    JDP2 was shown to maintain viral latency, binding the EBV BZLF1 promoter with HDAC3 to suppress lytic reactivation.

    Evidence EMSA, ChIP, RNAi, mutant virus analysis

    PMID:21525011

    Open questions at the time
    • Host signals that relieve JDP2 repression during reactivation undefined
  13. 2012 High

    In vivo KO confirmed JDP2's developmental roles, showing osteopetrosis from impaired osteoclastogenesis and defective neutrophil differentiation via histone-acetylation-dependent ATF3 suppression.

    Evidence Jdp2 KO mice, bone histology, neutrophil assays, ChIP

    PMID:23200825

    Open questions at the time
    • Cell-autonomous vs niche contributions to bone phenotype not fully separated
  14. 2019 High

    A genotoxic-stress redox function was defined: ATM-phosphorylated JDP2 nucleates a β-catenin/PRMT5 complex recruiting WDR5/MLL to activate glutathione-metabolic genes, showing JDP2 can also drive activating histone methylation.

    Evidence Co-IP, ChIP, histone-modification assays, WDR5 inhibitor (OICR-9429)

    PMID:31434880

    Open questions at the time
    • ATM phosphosite on JDP2 not mapped
    • Switch between repressive and activating modes mechanistically unresolved
  15. 2018 Medium

    An oncogenic survival role was established in T-ALL, where JDP2 activates MCL1 to confer apoptosis resistance and steroid resistance.

    Evidence shRNA knockdown, transgenic zebrafish, gene expression

    PMID:29941549

    Open questions at the time
    • Direct promoter occupancy at MCL1 not fully demonstrated
    • Cofactor dependence in leukemic cells unknown
  16. 2024 Medium

    Refining the JDP2-p53 relationship, JDP2 was shown to bind p53 via its C-terminus, lower MDM2, and enhance WT (but not mutant) p53 transactivation, indicating context-dependent activation rather than uniform repression.

    Evidence Co-IP, domain mapping, p53 reporter, CHX chase

    PMID:38473360

    Open questions at the time
    • Reconciliation with earlier Trp53-promoter repression unresolved
    • Mechanism of MDM2 reduction undefined
  17. 2024 Medium

    Partner-specific corepression was mapped in AML, where IRF2BP2 is recruited by the ATF7/JDP2 heterodimer to chromatin and restrains its inflammatory gene-activating output.

    Evidence Co-IP, ChIP-seq, IRF2BP2 KO with transcriptomics

    PMID:38801077

    Open questions at the time
    • Whether ATF7/JDP2 activates or represses depends on cofactor balance not fully defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How JDP2 toggles between repressive (HDAC3/p300-inhibition) and activating (PRMT5/WDR5/MLL, CHOP10, p53) chromatin outputs at a given locus — and how this is set by partner identity, post-translational modification, and stress state — remains unresolved.
  • No unified model linking dimer partner to activation vs repression
  • No structural model of the JDP2 chromatin-modifying complexes
  • Phosphosites beyond Thr148 and their ligases incompletely defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 5 GO:0098772 molecular function regulator activity 2 GO:0042393 histone binding 1 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005634 nucleus 3 GO:0000228 nuclear chromosome 2
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-8953897 Cellular responses to stimuli 4 R-HSA-1266738 Developmental Biology 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-1640170 Cell Cycle 2
Partners
ATF7CHOP10/DDIT3EP300HDAC3IRF2BP1JUNPRMT5TP53
Complex memberships
ATF7/JDP2 AP-1 heterodimerJDP2-CHOP10 heterodimerJDP2/HDAC3 corepressor complexβ-catenin/JDP2/PRMT5 complex

Evidence

Reading pass · 33 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 JDP2 recruits a histone deacetylase 3 (HDAC3) complex to the differentiation response element (DRE) in the c-jun promoter, thereby inhibiting ATF-2/p300-mediated transactivation and repressing retinoic acid-induced differentiation of F9 cells. ChIP assays showed the JDP2/HDAC3 complex is replaced by the p300 complex upon RA treatment, accompanied by changes in histone acetylation status. Transient transfection, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, reporter assays Molecular and cellular biology High 12052888
2006 JDP2 directly inhibits p300-mediated acetylation of core histones both in vitro and in vivo, requiring the N-terminal 35 residues and the DNA-binding region. JDP2 also exhibits histone-chaperone activity in vitro (nucleosome assembly assay). In vitro histone acetylation assay, in vivo acetylation assay, nucleosome assembly assay, deletion mutagenesis Nature structural & molecular biology High 16518400
2001 JDP2 is phosphorylated by c-Jun N-terminal kinase (JNK) both in vitro and in vivo; the phosphoacceptor site is Thr148, and substitution of Thr148 to Ala blocks JNK-dependent phosphorylation. JDP2 contains a putative JNK docking site. In vitro kinase assay, in vivo phosphorylation assay, site-directed mutagenesis (T148A) FEBS letters High 11602244
2011 Phosphorylation of JDP2 on Thr148 by JNK targets JDP2 for proteasomal degradation. Replacement of Thr148 with Ala stabilizes JDP2 under stimuli that activate JNK (serum, anisomycin, UV, cycloheximide), while T148E (phospho-mimetic) destabilizes it. A JNK inhibitor (SP600125) blocks degradation, whereas p38 and MEK inhibitors do not. The proteasome inhibitor MG132 rescues degradation. Site-directed mutagenesis, pharmacological inhibitors, cycloheximide chase, proteasome inhibitor rescue, western blot The Biochemical journal High 21463260
2001 JDP2 represses p53 transcription via a conserved atypical AP-1 site in the p53 promoter, thereby promoting cell survival following UV irradiation. Reporter assay, UV irradiation, cell viability assay, overexpression Molecular and cellular biology Medium 11287607
2003 JDP2 overexpression activates TRAP and cathepsin K gene promoters in RAW264.7 cells; retroviral expression of JDP2 in mouse primary bone marrow cells facilitates RANKL-induced formation of TRAP-positive multinuclear osteoclasts, and antisense oligonucleotides to JDP2 suppress sRANKL-induced osteoclast formation. Retroviral overexpression, transient transfection, antisense oligonucleotide knockdown, TRAP staining, promoter reporter assay The Journal of experimental medicine Medium 12707301
2012 In Jdp2−/− mice, osteoclastogenesis is impaired (osteopetrosis phenotype). Jdp2 directly suppresses ATF3 expression via inhibition of histone acetylation at the ATF3 promoter, and this suppression is required for normal neutrophil differentiation and bactericidal function. Jdp2 knockout mouse, bone histology, neutrophil differentiation assays, ChIP for histone acetylation, gene expression analysis Immunity High 23200825
2009 JDP2-deficient MEFs exhibit resistance to replicative senescence. In the absence of JDP2, increased H3K27 methylation at the p16Ink4a promoter occurs, and Polycomb repressive complexes (PRC-1 and PRC-2) bind efficiently to repress p16Ink4a. Conversely, JDP2 overexpression induces p16Ink4a and p19Arf expression. Jdp2 KO MEFs, ChIP for H3K27 methylation and PRC binding, gene expression, overexpression The Journal of biological chemistry High 19233846
2010 JDP2 is recruited to the AP-1 site in the cyclin-A2 (Ccna2) promoter and represses its transcription. Jdp2 KO MEFs and TPA-treated skin show elevated cyclin-A2 mRNA and increased cell proliferation; reintroduction of JDP2 represses Ccna2 transcription and cell-cycle progression. Jdp2 KO mice, ChIP at cyclin-A2 promoter, qRT-PCR, colony formation, re-expression rescue Oncogene High 20802531
2007 JDP2 represses adipocyte differentiation by inhibiting histone H3 acetylation at the C/EBPδ gene promoter, thereby suppressing C/EBPδ transcription. Jdp2 KO MEFs show higher susceptibility to adipocyte differentiation and elevated C/EBP family gene expression. Jdp2 KO mice/MEFs, ChIP for histone H3 acetylation, promoter reporter assay, adipocyte differentiation assay Cell death and differentiation High 17464331
2002 Ectopic expression of JDP2 in C2C12 myoblasts inhibits cell-cycle progression and induces spontaneous muscle cell differentiation; JDP2 induces p38 kinase activity in both C2 and RD cells programmed to differentiate. Ectopic overexpression, cell-cycle analysis, myotube formation assay, p38 kinase activity assay The Journal of biological chemistry Medium 12171923
2009 JDP2 suppresses ATF3 transcription by binding to both a consensus ATF/CRE site and a non-consensus ATF3 auto-repression element in the ATF3 promoter. JDP2 KO MEFs display elevated ATF3 protein and potentiated ATF3 induction in response to serum or ER stress; JDP2 overexpressing mice show attenuated ATF3 induction. JDP2 KO MEFs, JDP2 overexpression transgenic mice, promoter reporter assay, western blot, serum/ER stress stimulation Nucleic acids research High 19233874
2008 JDP2 forms a heterodimer with CHOP10 (C/EBP homologous protein) via leucine zipper motifs; the basic domain of CHOP10 contributes to DNA binding. This JDP2-CHOP10 complex strongly activates transcription from TPA-response element (TRE)-containing promoters but not CRE-containing promoters, both in vitro and in vivo (EMSA and ChIP). JDP2 overexpression increases cell viability after ER stress and counteracts CHOP10 pro-apoptotic activity. Co-immunoprecipitation, EMSA, ChIP, reporter assay, cell viability assay Nucleic acids research High 18463134
2009 JDP2 interacts with the progesterone receptor (PR) through its bZIP domain; NMR chemical shift mapping shows that JDP2 binding residues reside predominantly within the carboxyl-terminal extension (CTE) of the PR DNA-binding domain. Point mutations and CTE domain swap experiments confirm that JDP2-CTE interaction is functionally required for enhancement of PR transcriptional activity. NMR chemical shift mapping, peptide competition, site-directed mutagenesis, CTE domain swap, transcriptional reporter assay The Journal of biological chemistry High 19553667
2011 JDP2 binds the ZII cis-element (an ATF/CRE/AP-1 binding site) in the Epstein-Barr virus BZLF1 promoter (Zp), and this binding correlates with HDAC3 association and reduced histone acetylation at Zp. Silencing of endogenous JDP2 by RNAi increases viral early gene products and viral DNA replication, indicating JDP2 maintains EBV latency. Reporter assay, EMSA, ChIP, mutant virus analysis, RNAi knockdown The Journal of biological chemistry High 21525011
2008 IRF2-BP1 (IRF2-binding protein-1) was identified as a JDP2-binding protein and acts as a JDP2 ubiquitin ligase via its RING-finger domain, enhancing polyubiquitination of JDP2. IRF2-BP1 also represses ATF2-mediated transcriptional activation from a CRE-containing promoter. Epitope-tagging pulldown, polyubiquitination assay, reporter assay FEBS letters Medium 18671972
2008 JDP2 acts as a repressor of CHOP transcription by binding to the amino acid response element (AARE) in the CHOP promoter in unstimulated cells; its binding decreases following amino acid starvation. JDP2 is functionally associated with HDAC3 to inhibit CHOP transcription. EMSA, ChIP, reporter assay, amino acid starvation FEBS letters Medium 18396163
2012 JDP2 transcriptionally represses the Trp53 promoter via an atypical AP-1 site; JDP2 expression negatively regulates Trp53 expression levels in a leukaemogenesis context. Transposon insertional mutagenesis screen, promoter reporter assay, gene expression analysis Oncogene Medium 22370638
2018 JDP2 directly regulates MCL1 transcription; depletion of JDP2 by shRNA knockdown leads to apoptosis in T-ALL cells. JDP2-overexpressing zebrafish thymocytes express high levels of mcl1 and demonstrate steroid resistance in vivo. shRNA knockdown, transcriptional reporter/ChIP (implied by 'direct transcriptional regulation'), transgenic zebrafish model, gene expression analysis The Journal of experimental medicine Medium 29941549
2019 Upon genotoxic stress, ATM phosphorylates JDP2, enabling formation of a β-catenin/JDP2/PRMT5 chromatin complex. This complex recruits WDR5/MLL methyltransferase complexes, producing H3R2me1/H3R2me2s and H3K4 methylation at promoters of GSH-metabolic cascade genes, reestablishing glutathione homeostasis and reducing ROS. Co-immunoprecipitation, ChIP, histone modification assays, pharmacological inhibition (OICR-9429), genotoxic stress treatment Nature communications High 31434880
2016 JDP2 acts as a repressor of FSHβ (Fshb) transcription by occupying the AP-1-binding site in the Fshb promoter in a complex with c-JUN. GNRH treatment induces c-FOS to replace JDP2 as c-JUN's binding partner, forming transcriptionally active AP-1; rapid c-FOS degradation then allows reformation of the repressive JDP2 complex. Jdp2 null female mice show elevated FSH, early puberty, and early reproductive senescence. ChIP, co-immunoprecipitation, reporter assay, Jdp2 KO mouse reproductive phenotype analysis The Journal of biological chemistry High 28007961
2014 Zebrafish doublecortin-like protein kinase (DCLK) C-terminal kinase domain binds JDP2 (identified by two-hybrid screening) and efficiently phosphorylates JDP2 in the presence of histone. Yeast two-hybrid screening, in vitro kinase assay with histone Biochemical and biophysical research communications Low 24582561
2019 ATF3 and JDP2 double-deficient cancer-associated fibroblasts secrete elevated levels of SDF-1 (CXCL12), promoting tumor growth and vascular perfusion. ATF3 and JDP2 regulate SDF-1 transcription and secretion in fibroblasts, and this is potentiated in the presence of cancer cells. SDF-1 depletion in dKO fibroblasts dampened tumor growth. Double KO mouse, tumor implantation, ELISA, conditioned medium assay, SDF-1 depletion rescue Oncogene Medium 30670778
2020 In Jdp2 KO cerebellar granule cell progenitors (GCPs), p21Cip1 and Nrf2 form a complex that binds antioxidant response elements in the Slc7a11 promoter, increasing Slc7a11 (xCT cystine-glutamate exchanger) expression and glutathione levels, thus reducing ROS and conferring resistance to ROS-mediated apoptosis. Jdp2 KO mice, primary GCP cultures, ChIP, co-immunoprecipitation, ROS measurement, apoptosis assay Scientific reports Medium 32188872
2021 JDP2 forms an activation complex with AHR-ARNT and NRF2-sMAF at dioxin response elements (DRE) and antioxidant response elements (ARE) in the AHR promoter in response to DMSO, regulating AHR promoter activity and ROS production. Jdp2 is required for AHR promoter activation; co-immunoprecipitation and ChIP confirmed JDP2 presence in the complex at DRE sites. Co-immunoprecipitation, ChIP, promoter reporter assay, Jdp2 KO MEFs, DMSO treatment Cell biology and toxicology Medium 33723743
2020 JDP2 is directly regulated at the transcriptional level by ATF4; JDP2 knockdown enhances expression of ATF4 target genes including ASNS, DR4, and DR5. JDP2 overexpression represses ER stress-mediated DR5 promoter activation (transient reporter assay). JDP2 knockdown increases TRAIL sensitivity in HeLa cells, indicating JDP2 functions as a negative feedback regulator of the ATF4 pathway to confer TRAIL resistance. siRNA knockdown, reporter assay, western blot, TRAIL sensitivity assay FEBS open bio Medium 33108704
2024 JDP2 directly interacts with p53 via its C-terminal domain (confirmed by co-IP and domain mapping). JDP2 enhances p53 transactivation in p53-null H1299 cells reconstituted with WT p53 but fails to enhance transactivation of hotspot mutant p53. JDP2 reduces MDM2 levels to enhance p53 transactivation, and slightly stabilizes p53 in CHX chase experiments. Co-immunoprecipitation, domain deletion analysis, reporter assay (p53 14X RE-Luc), CHX chase, western blot Cancers Medium 38473360
2014 p53 significantly represses the transcriptional activity of the JDP2 promoter, suggesting a negative feedback loop between JDP2 (which represses p53) and p53 (which represses JDP2). Promoter cloning, reporter assay, primer extension analysis Biochemical and biophysical research communications Medium 25026555
2022 JDP2 transcriptionally suppresses ITGBL1 promoter activity (dual-luciferase assay); ITGBL1 overexpression reverses the effects of JDP2 upregulation on pancreatic cancer cell proliferation, migration, and invasion. Dual-luciferase reporter assay, gain/loss-of-function, cell proliferation and invasion assays Brazilian journal of medical and biological research Low 35584452
2022 JDP2 directly activates PDE4B transcription in cardiomyocytes (confirmed by dual-luciferase reporter and ChIP assays); JDP2 overexpression upregulates PDE4B expression and exacerbates hypoxia/reoxygenation-induced H9c2 cell injury. Dual-luciferase reporter assay, ChIP, overexpression, hypoxia/reoxygenation model Experimental and therapeutic medicine Medium 35401806
2024 IRF2BP2 interacts with the AP-1 heterodimer ATF7/JDP2, is recruited to chromatin by ATF7/JDP2, and counteracts its gene-activating function in AML cells. Loss of IRF2BP2 leads to overactivation of inflammatory pathways driven by ATF7/JDP2. Co-immunoprecipitation, ChIP-seq, loss-of-function (IRF2BP2 KO), gene expression analysis Nucleic acids research Medium 38801077
2019 A combination of Jdp2 with six other factors (Jhdm1b, Mkk6, Glis1, Nanog, Essrb, Sall4) can reprogram mouse embryonic fibroblasts to chimera-competent iPSCs. ATAC-seq and RNA-seq reveal that Jdp2 participates in dynamically closing and opening chromatin loci as part of a cooperative reprogramming process. Reprogramming assay, RNA-seq, ATAC-seq, chimera injection, dropout experiments Cell reports Medium 31216469
2017 CGRP suppresses β-glucan-induced inflammation and osteoclast multinucleation via direct suppression of NF-κB p65 by the transcriptional repressor Jdp2. In vivo nociceptor ablation, TRPV1/TRPA1 knockout, CGRP treatment, inflammatory readout, mechanistic pathway dissection Cell reports Medium 28658621

Source papers

Stage 0 corpus · 63 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 Nociceptors Boost the Resolution of Fungal Osteoinflammation via the TRP Channel-CGRP-Jdp2 Axis. Cell reports 96 28658621
2002 JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Molecular and cellular biology 87 12052888
2003 Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. The Journal of experimental medicine 75 12707301
2006 Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nature structural & molecular biology 69 16518400
2012 The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity 67 23200825
2001 AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation. Molecular and cellular biology 61 11287607
2002 Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells. The Journal of biological chemistry 52 12171923
2007 JDP2 suppresses adipocyte differentiation by regulating histone acetylation. Cell death and differentiation 50 17464331
2010 Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2. Oncogene 49 20802531
2019 Induction of Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Jdp2-Jhdm1b-Mkk6-Glis1-Nanog-Essrb-Sall4. Cell reports 44 31216469
2009 The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3. Nucleic acids research 43 19233874
2001 The AP-1 repressor, JDP2, is a bona fide substrate for the c-Jun N-terminal kinase. FEBS letters 43 11602244
2010 The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Molecular cancer 42 20214788
2019 Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. Nature communications 40 31434880
2013 Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovascular research 37 23612584
2008 TRE-dependent transcription activation by JDP2-CHOP10 association. Nucleic acids research 35 18463134
2009 JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. The Journal of biological chemistry 33 19233846
2020 Down-regulated lncRNA AGAP2-AS1 contributes to pre-eclampsia as a competing endogenous RNA for JDP2 by impairing trophoblastic phenotype. Journal of cellular and molecular medicine 29 32150333
2013 Preeclamptic plasma induces transcription modifications involving the AP-1 transcriptional regulator JDP2 in endothelial cells. The American journal of pathology 29 24120378
2009 A progesterone receptor co-activator (JDP2) mediates activity through interaction with residues in the carboxyl-terminal extension of the DNA binding domain. The Journal of biological chemistry 29 19553667
2018 JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. The Journal of experimental medicine 26 29941549
2019 ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene 25 30670778
2016 c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice. The Journal of biological chemistry 24 28007961
2011 Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. The Journal of biological chemistry 24 21525011
2005 Tumor model-specific proviral insertional mutagenesis of the Fos/Jdp2/Batf locus. Virology 24 15913695
2005 Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis. Biochimica et biophysica acta 23 16026868
2012 Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene 22 22370638
2008 Role of the repressor JDP2 in the amino acid-regulated transcription of CHOP. FEBS letters 22 18396163
2018 JDP2 overexpression provokes cardiac dysfunction in mice. Scientific reports 20 29769710
2008 IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription. FEBS letters 20 18671972
2009 Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nucleic acids research 19 19502497
2019 JDP2 and ATF3 deficiencies dampen maladaptive cardiac remodeling and preserve cardiac function. PloS one 15 30818334
2011 Phosphorylation of JDP2 on threonine-148 by the c-Jun N-terminal kinase targets it for proteosomal degradation. The Biochemical journal 15 21463260
2010 Histone chaperone Jun dimerization protein 2 (JDP2): role in cellular senescence and aging. The Kaohsiung journal of medical sciences 15 20950777
2021 Dimethyl sulfoxide stimulates the AhR-Jdp2 axis to control ROS accumulation in mouse embryonic fibroblasts. Cell biology and toxicology 13 33723743
2011 The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines. Pathology oncology research : POR 13 22109562
2023 Jdp2 is a spatiotemporal transcriptional activator of the AhR via the Nrf2 gene battery. Inflammation and regeneration 11 37596694
2014 Nuclear translocation of doublecortin-like protein kinase and phosphorylation of a transcription factor JDP2. Biochemical and biophysical research communications 11 24582561
2012 JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 11 22535371
2020 Jdp2-deficient granule cell progenitors in the cerebellum are resistant to ROS-mediated apoptosis through xCT/Slc7a11 activation. Scientific reports 10 32188872
2020 Structural, Pro-Inflammatory and Calcium Handling Remodeling Underlies Spontaneous Onset of Paroxysmal Atrial Fibrillation in JDP2-Overexpressing Mice. International journal of molecular sciences 9 33265909
2015 Host JDP2 expression in the bone marrow contributes to metastatic spread. Oncotarget 8 26497998
2003 Sequence specific transcription factor, JDP2 interacts with histone and inhibits p300-mediated histone acetylation. Nucleic acids research. Supplement (2001) 8 14510502
2025 The AHR-NRF2-JDP2 gene battery: Ligand-induced AHR transcriptional activation. Biochemical pharmacology 7 39855429
2021 JDP2, a Novel Molecular Key in Heart Failure and Atrial Fibrillation? International journal of molecular sciences 7 33923401
2020 JDP2 is directly regulated by ATF4 and modulates TRAIL sensitivity by suppressing the ATF4-DR5 axis. FEBS open bio 7 33108704
2014 Cloning and characterization of the mouse JDP2 gene promoter reveal negative regulation by p53. Biochemical and biophysical research communications 7 25026555
2002 Transcriptional regulation of the c-jun gene by AP-1 repressor protein JDP2 during the differentiation of F9 cells. Nucleic acids research. Supplement (2001) 7 12903123
2024 IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic acids research 6 38801077
2021 Deletion of Jdp2 enhances Slc7a11 expression in Atoh-1 positive cerebellum granule cell progenitors in vivo. Stem cell research & therapy 6 34187574
2023 Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL. Blood advances 4 36897249
2022 ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 4 35584452
2018 Deletion of JDP2 improves neurological outcomes of traumatic brain injury (TBI) in mice: Inactivation of Caspase-3. Biochemical and biophysical research communications 4 30217453
2004 Histone modification activities of JDP2 associated with retinoic acid-induced differentiation of F9 cells. Nucleic acids symposium series (2004) 4 17150542
2024 Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis. Cells 3 39404411
2024 Trans-differentiation of Jdp2-depleted Gaba-receptor-positive cerebellar granule cells to Purkinje cells. Cell death discovery 3 39695141
2023 Palmitic acid-induced microRNA-143-5p expression promotes the epithelial-mesenchymal transition of retinal pigment epithelium via negatively regulating JDP2. Aging 3 37179125
2022 Transcription factor JDP2 activates PDE4B to participate in hypoxia/reoxygenation-induced H9c2 cell injury. Experimental and therapeutic medicine 3 35401806
2024 Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2. Cancers 2 38473360
2025 Down-Regulated JDP2 Attenuated Trophoblast Invasion and Migration in Preeclampsia by Inhibiting Epithelial-Mesenchymal Transition through the Wnt/β-Catenin Pathway. Current protein & peptide science 1 39171471
2025 Maintenance and Reversibility of Paroxysmal Atrial Fibrillation in JDP2 Overexpressing Mice. Cells 0 40710332
2020 Author Correction: Jdp2-deficient granule cell progenitors in the cerebellum are resistant to ROS-mediated apoptosis through xCT/Slc7a11 activation. Scientific reports 0 32528039
2010 Epigenetic regulation of p16Ink4a and Arf by JDP2 in cellular senescence. Biomolecular concepts 0 25961985

Missed literature

Know a paper Affinage missed for JDP2? Flag it for the maintainers and the community.

No submissions yet.